Annamycin liposomal

Drug Profile

Annamycin liposomal

Alternative Names: Annamycin liposomal - University of Texas M.D. Anderson Cancer Center; Annamycin-LF; L-ANNA; L-annamycin; Liposomal annamycin; S-ANNA

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Aronex Pharmaceuticals; Callisto Pharmaceuticals; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lymphoblastic leukaemia; Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Discontinued Acute lymphoblastic leukaemia; Breast cancer; Cancer; Chronic myeloid leukaemia

Most Recent Events

  • 14 Aug 2017 Moleculin anticipates to file a clinician sponsored IND for WP1066 for treatment of adult brain tumours in the second half of 2017
  • 18 Jul 2017 Moleculin signs a new technology license agreement with MD Anderson Cancer Center for annamycin for the treatment of acute myeloid leukaemia
  • 18 Jul 2017 Preclinical trials in Acute myeloid leukaemia in USA (IV) (Moleculin Biotech pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top